Brind.

Carl H. June pioneered FDA-approved CAR-T cell therapy on September 2, 2025.

2 reports, 2 independent Updated Jun 16

Gone quiet

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Carl H. June pioneered FDA-approved CAR-T cell therapy on September 2, 2025.

Who's involved

What this event is mainly about

FDA Carl H. June

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Carl H. June
American immunologist

Nothing else this week.

Related events

Coverage

Newest first; wire copies grouped

Jun 16finanznachrichten.de
Sep 2GlobeNewswireCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the